12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Tuesday's pre-market session, several healthcare stocks showed significant movement. Regulus Therapeutics led the gainers with an 84.8% increase, while Renalytix faced the largest drop among the losers, declining by 27.2%. Notably, Bioventus and CytomX Therapeutics released their Q4 earnings, influencing their stock prices.
March 12, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CytomX Therapeutics stock declined by 17.63% to $2.07 after its Q4 earnings were released, with a market cap of $138.5 million.
The decline in CTMX stock price post-Q4 earnings suggests the financial results did not meet investor expectations.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 80
NEGATIVE IMPACT
Renalytix shares fell 27.2% to $0.83, with a market cap of $41.4 million.
The sharp decline in RNLX stock price suggests negative investor sentiment, possibly due to disappointing news or financial results.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Bioventus shares increased by 16.0% to $6.16 after releasing Q4 earnings, with a market cap of $387.8 million.
The increase in BVS stock price following its Q4 earnings release suggests the financial results were favorable and well-received by investors.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 80
POSITIVE IMPACT
Regulus Therapeutics stock surged 84.8% to $2.55, with a market cap of $51.5 million.
The significant surge in RGLS stock price indicates strong investor confidence, potentially due to positive news or expectations.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90